Author:
Yolchuyeva Sevinj,Giacomazzi Elena,Tonneau Marion,Lamaze Fabien,Orain Michele,Coulombe François,Malo Julie,Belkaid Wiam,Routy Bertrand,Joubert Philippe,Manem Venkata S. K.
Abstract
AbstractWith the increasing use of immune checkpoint inhibitors (ICIs), there is an urgent need to identify biomarkers to stratify responders and non-responders using programmed death-ligand (PD-L1) expression, and to predict patient-specific outcomes such as progression free survival (PFS). The current study is aimed to determine the feasibility of building imaging-based predictive biomarkers for PD-L1 and PFS through systematically evaluating a combination of several machine learning algorithms with different feature selection methods. A retrospective, multicenter study of 385 advanced NSCLC patients amenable to ICIs was undertaken in two academic centers. Radiomic features extracted from pretreatment CT scans were used to build predictive models for PD-L1 and PFS (short-term vs. long-term survivors). We first employed the LASSO methodology followed by five feature selection methods and seven machine learning approaches to build the predictors. From our analyses, we found several combinations of feature selection methods and machine learning algorithms to achieve a similar performance. Logistic regression with ReliefF feature selection (AUC = 0.64, 0.59 in discovery and validation cohorts) and SVM with Anova F-test feature selection (AUC = 0.64, 0.63 in discovery and validation datasets) were the best-performing models to predict PD-L1 and PFS. This study elucidates the application of suitable feature selection approaches and machine learning algorithms to predict clinical endpoints using radiomics features. Through this study, we identified a subset of algorithms that should be considered in future investigations for building robust and clinically relevant predictive models.
Funder
Nuovo-Soldati Cancer Research Foundation
Oncopole
Terry Fox clinician scientist
Fonds de Recherche du Québec - Santé
Quebec Heart & Lung Institute Research Center
Publisher
Springer Science and Business Media LLC
Reference45 articles.
1. Borghaei, H. & Brahmer, J. Nivolumab in nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 374(5), 493–494 (2016).
2. Alexander, M., Ko, B., Lambert, R., Gadgeel, S. & Halmos, B. The evolving use of pembrolizumab in combination treatment approaches for non-small cell lung cancer. Expert Rev. Respir. Med. 17, 1–11 (2019).
3. Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373(2), 123–135 (2015).
4. Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373(17), 1627–1639 (2015).
5. Dercle, L. et al. Early readout on overall survival of patients with melanoma treated with immunotherapy using a novel imaging analysis. JAMA Oncol. 8(3), 385–392 (2022).
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献